For example, ZUMA-1 (axicabtagene ciloleucel or axi-cel, which is the CD28 costimulatory domain) and JULIET (tisagenlecleucel or tisa-cel, which is the 4-1BB co-stimulatory domain) act as anti-CD19 CART (CAR19) in relapsed or refractory diffuse large B-cell lymphoma and multiple myeloma, as well as non-Hodgkin’s B-cell lymphoma (Frigault and Maus, 2020). This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.